A study of oral EMA401 in the treatment of pain following shingles to see if EMA401 can reduce the level of pain.

Phase 1

• Conditions: postherpetic neuralgia; MedDRA version: 14.0Level: PTClassification code 10036376Term: Post herpetic neuralgiaSystem Organ Class: 10029205 - Nervous system disorders; Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

• Registration Number: EUCTR2011-000977-29-BG
• Lead Sponsor: Spinifex Pharmaceuticals Pty Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-08-16
• Last Update Posted: 3 April 2017

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 172

Inclusion Criteria

1.Be able to give voluntary written informed consent to participate in the study.
2.Be over 18 years of age.
3.Be diagnosed as suffering from PHN defined as pain persisting for more than six months after onset of herpes zoster rash.
4.Be diagnosed as suffering from moderate to severe pain across the Screening Period. The assessment of moderate and severe pain will be made using an algorithm proprietary to Spinifex Pharmaceuticals. The investigator will be informed immediately as to whether the patient is eligible or ineligible on entering all the relevant pain scores in the electronic data capture portal.
5.Willing and be able to comply with all study procedures.
6.For females, have a negative pregnancy test at the Screening visit (Visit 1) and at Visit 2 (Day 1) prior to administration of study medication.
7.For females, be of non-child-bearing potential (i.e. either surgically sterilised or one year post-menopausal), or if of child-bearing potential, must have used adequate contraceptive precautions for 30 days prior to Screening, and must agree to use two approved methods of contraception for the duration of the study, and for one month after administration of the last dose of study medication.
For males: Agrees to use two approved methods of contraception for the duration of the study and until one month after administration of the last dose of the study medication.
Approved methods of contraception include:
•Surgical sterilization (vasectomy at least six months prior to dosing)
•Condom use by male partners of female patients or by male patients.
•Birth control pills, diaphragm with vaginal spermicide, intra uterine device (IUD), contraceptive hormonal patches, implants or injections by female patients or female partners of male patients
8.Be fluent in the language of the endpoint scales provided to patients in the study.
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 104
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 68

Exclusion Criteria

1.Be currently receiving any of the prohibited medications listed below and in Section 7.7.2 or have received within 30 days prior to the Screening visit (Visit 1) or is anticipated to receive after the start of the trial (i.e. on or after Visit 1) any new prescription systemic or topical medication for their PHN. Patients may be enrolled if stable on therapy for their PHN as specified in the permitted medications with restrictions below and in Section 7.7.1
2.Have received an investigational drug within 30 days or 10 half-lives of the drug, whichever is longer, prior to the Screening visit (Visit 1) or have previously received EMA401.
3.Known to be allergic to EMA401 or any of the excipients or who have a history of an allergic reaction to previous medication that required management by a health care professional.
4.Have a clinically significant history of systemic allergic disease (e.g., urticaria, atopic dermatitis).
5.Have a blood pressure, after resting for at least 5 minutes, outside a systolic blood pressure range of 100-150 mmHg or a diastolic blood pressure outside a range of 50-90 mmHg on two consecutive measurements (at least 10 minutes apart and completed within 20 minutes of the initial measurement).
6.Have a pulse rate, after sitting for at least 5 minutes, greater than 100 beats per minute (bpm) or lower than 50 bpm, or 45 bpm if on beta blockers, on two consecutive measurements (at least 10 minutes apart and completed within 20 minutes of the initial measurement).
7.Known to be diabetic.
8.Consume more than four units of alcohol daily for a man or three units of alcohol for a woman (one unit = 300 mL beer, one glass of wine, one measure of spirits) or has a history of alcohol abuse/dependence.
9.Have evidence of significant renal insufficiency, indicated by an estimated creatinine clearance using the Cockcroft-Gault formula of less than 50 mL/min at Screening (Visit 1).
10.Have serum aspartate transaminase (AST), gamma glutamyl transaminase (GGT) or alanine transaminase (ALT) levels greater than 3.0 x the upper limit of normal or have total bilirubin concentrations greater than 2.0 x the upper limit of normal at Screening (Visit 1).
11.Other than pain as a result of postherpetic neuralgia, have an active, uncontrolled medical condition (e.g., neurological, gastrointestinal, renal, hepatic, cardiovascular, pulmonary, metabolic, endocrine, haematological, genitourinary or other major disorder), or psychiatric illness (e.g., depression, schizophrenia), or any other significant clinical disorder or laboratory finding that in the opinion of the investigator, precludes participation in the study or may interfere with the study objectives.
12.Other than pain as a result of postherpetic neuralgia, have had a clinically significant illness or operative procedure within 4 weeks of the Screening visit (Visit 1) (e.g. influenza, myocardial infarction).
13. Have undergone neurolytic or neurosurgical therapy for postherpetic neuralgia.
14.Have other moderate to severe pain condition that may confound the self-evaluation of pain due to postherpetic neuralgia.
15.Have skin conditions in the affected area that in the investigator’s opinion could alter sensation.
16.Have active herpes zoster upon physical examination at Screening (Visit 1) or during the study.
17.Have hepatitis B (HBV), hepatitis C (HCV) or human immunodeficiency virus (HIV) infection as defined by being seropositive for hepatitis B surface antigen

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified